Is renal cell carcinoma hereditary?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Kidney Cancer Hereditary?

Yes, kidney cancer can be hereditary, with approximately 5% of renal cell carcinomas (RCCs) associated with inherited genetic mutations, though the majority of cases are sporadic. 1, 2, 3

Hereditary RCC Syndromes

Multiple well-characterized hereditary syndromes significantly increase kidney cancer risk, each with distinct genetic causes and clinical features:

Major Hereditary RCC Syndromes

  • Von Hippel-Lindau (VHL) disease – the most common hereditary RCC syndrome, caused by VHL gene mutations 1, 3
  • Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) – caused by fumarate hydratase (FH) gene mutations, characterized by cutaneous/uterine leiomyomas and aggressive RCC 4
  • Birt-Hogg-Dubé (BHD) syndrome – associated with skin lesions, lung cysts, and RCC 1, 3
  • Tuberous Sclerosis – caused by TSC1/TSC2 mutations with multisystem manifestations including RCC 1, 3
  • Hereditary Papillary RCC (HPRCC) – caused by activating MET oncogene mutations, affecting only kidneys 1
  • Succinate Dehydrogenase (SDH)-Deficient RCC – linked to SDH gene mutations 3
  • BAP1 Tumor Predisposition Syndrome – associated with multiple cancer types including RCC 3

Who Should Be Evaluated for Hereditary RCC?

Genetic risk assessment should be considered for patients meeting specific clinical criteria 5:

  • Family history of RCC in first-degree relatives
  • Bilateral or multifocal RCC
  • Early-onset RCC (age ≤46 years or two or more primary RCCs before age 60) 5, 6
  • Specific histologic subtypes suggesting hereditary syndromes 5
  • Syndromic features such as skin lesions, uterine leiomyomas, or other extrarenal manifestations 4

Surveillance Recommendations for HLRCC (Example Protocol)

For confirmed carriers of pathogenic FH variants, annual renal MRI surveillance should begin at age 8-10 years 4:

  • MRI with renal protocol is preferred over ultrasound due to superior sensitivity 4
  • Diffusion-weighted imaging without gadolinium contrast is recommended for routine screening to avoid gadolinium retention concerns 4
  • Contrast-enhanced MRI should be performed only if a lesion is detected for characterization 4
  • Annual skin examinations by a pediatrician starting at diagnosis, with dermatology referral as needed 4
  • Gynecologic surveillance beginning at age 20 or earlier if symptomatic 4

HLRCC-Specific Risk Profile

The age-related RCC penetrance in HLRCC demonstrates lifelong risk: 1% by age 15,2% by age 20, and 21% by age 70 4. Fifteen pediatric cases have been reported, all in the second decade of life 4.

Genetic Testing Approach

Multigene panel testing is now the standard approach rather than single-gene testing 5:

  • Testing should include both sequencing and deletion/duplication analysis (e.g., multiplex ligation-dependent probe amplification) 4
  • Predictive testing of at-risk family members should begin at age 8 years for syndromes like HLRCC 4
  • Recent studies show that expanded cancer gene panels can identify pathogenic variants in 16% of patients with hereditary RCC features, including variants in BRIP1, CHEK2, MITF, and BRCA1 6

Clinical Implications

Most hereditary RCC syndromes are inherited in an autosomal dominant pattern with incomplete penetrance 4. These syndromes typically involve tumor suppressor genes requiring somatic inactivation of the remaining allele for malignant progression 1.

Important Caveats

  • Genotype-phenotype correlations have not been convincingly demonstrated for most hereditary RCC syndromes, meaning all carriers face comparable risks regardless of specific mutation type 4
  • Emerging genetic associations continue to be identified, suggesting further locus heterogeneity beyond currently recognized genes 6
  • The clinical utility of expanded panel testing requires ongoing validation, particularly for rarer genotype-phenotype associations 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.